SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
99
|
B-Cell Responses To HIV Infection: Challenges and Opportunities
Susan L. Moir
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
NeuroHIV in 2014: Beyond Dementia
Serena S. Spudich
Yale University, New Haven, CT, United States
A 15-Year Review of Maternal Deaths in a Background of Changing HIV Management Guidelines
Coceka N. Mnyani
Anova Health Institute, Johannesburg, South Africa and University of the Witwatersrand, Johannesburg, South Africa
Incidence and Cofactors of Acute HIV During Pregnancy and Postpartum
John Kinuthia
Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya
Efficacy and Safety of LPV/r Versus EFV in HIV+ Pregnant and Breast-Feeding Ugandan Women
Deborah Cohan
OBGYN, University of California San Francisco, San Francisco, CA, United States
Infant Lopinavir/r Versus 3TC To Prevent Postnatal HIV-1 Transmission: The ANRS 12174 Trial
Chipepo Kankasa
Department of Paediatrics and Child Health, University Teaching Hospital, Lusaka, Zambia
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate
George K. Siberry
NICHD, Maternal and Pediatric Infectious Disease Branch, NIH, Bethesda, MD, United States
Virologic Control by 1 Year of Age Significantly Reduces HIV-1 Reservoirs in Perinatal Infection
Deborah Persaud
Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Virologic Efficacy of Efavirenz Maintenance Therapy in Nevirapine Prophylaxis-ExposedChildren
Ashraf Coovadia
University of the Witwatersrand, Johannesburg, South Africa
Final Results of Koncert: A Randomized Noninferiority Trial of QD Vs BD LPV/r Dosing in Children
Hermione Lyall
Imperial College London, London, United Kingdom
Very Early Combination Antiretroviral Therapy in Perinatal HIV Infection: Two Case Studies
Deborah Persaud
Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Pyroptosis Drives Both CD4 T Cell Death and Chronic Inflammation in HIV-Infected Lymphoid Tissues
Gilad Doitsh
Gladstone Institute of Virology and Immunology, San Francisco, CA, United States
Early ART Initiation Prevents Disruption of the Mucosal Barrier and Subsequent T-Cell Activation
Alexandra Schuetz
Retrovirology, USAMC-AFRIMS, Bangkok, Thailand
Characterizing the IFNα Resistance of Transmitted Founder HIV-1
Shilpa S. Iyer
Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia, PA, United States
Identification of IFI16 as HIV Restriction Factor
Amalio Telenti
University of Lausanne, Lausanne, Switzerland
Central Memory and Effector Memory CD4 T Cells From HIV Controllers Harbor Distinct HIV Strains
Eli Boritz
Human Immunology Section, Vaccine Research Center, Bethesda, MD, United States
Accelerated Viral Load Increase and CD4 Decline in HIV-1 Superinfected Women
Keshet Ronen
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Selection for Active SAMHD1 Antagonism in Natural Infections of SIVagm
Chelsea Spragg
Molecular and Cellular Biology, University of Washington, Seattle, WA, United States and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Probiotic and IL-21 Treatment Promotes Th17 Cell Recovery in ARV-Treatment of Pigtail Macaques
Alexandra M. Ortiz
LMM, NIH, Bethesda, MD, United States
First-Line RAL + DRV/r Is Non-Inferior To TDF/FTC + DRV/r: The NEAT001/ANRS143 Randomised Trial
François Raffi
University Hospital, Nantes, France
Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir With FTC/Tenofovir: ACTG 5257
Raphael J. Landovitz
Center for Clinical AIDS Research & Education, University of California Los Angeles, Los Angeles, CA, United States
Attachment Inhibitor Prodrug BMS-663068 in ARV-Experienced Subjects: Week 24 Analysis
Jacob Lalezari
Quest Clinical Research, San Francisco, CA, United States
Sensitive Screening Reveals Widespread Underestimation of Transmitted HIV Drug Resistance
Jeffrey A. Johnson
Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States
Transmitted HIV-1 Drug Resistance Between Partner-Pairs
Lisa M. Frenkel
University of Washington, Seattle, WA, United States and Seattle Children's Hospital, Seattle, WA, United States
Silent Mutations in HIV-1 Subtype B Reverse Transcriptase Selected by ART Restore Viral Fitness
Sushama Telwatte
Centre for Biomedical Research, Burnet Institute, Melbourne, Australia and Department of Microbiology, Monash University, Melbourne, Australia
Reduced In Vivo Replicative Capacity of Drug-Resistant SHIV During Acute Infection
J. Gerardo Garcia-Lerma
Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States
744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results
David Margolis
GSK, RTP, NC, United States
Safety and Antiviral Effect of MK-1439, A Novel NNRTI (+FTC/TDF) in ART-Naive HIV-Infected Patients
Javier O. Morales-Ramirez
Clinical Research Puerto Rico, San Juan, Puerto Rico
A Phase 2 Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Pulmonary TB Treatment
Susan E. Dorman
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Tuberculosis Infection in Early Childhood in Uganda and the Influence of HIV Exposure
Carina Marquez
University of California, San Francisco, San Francisco, CA, United States
Effect of Xpert MTB/RIF On Early Mortality in Adults With Suspected TB: A Pragmatic Randomized Trial
Gavin Churchyard
Aurum Institute, Houghton, South Africa
Xpert as the First-Line TB Test in South Africa: Yield, Initial Loss To Follow-Up, Proportion Treated
Katherine L. Fielding
London School of Hygiene & Tropical Medicine, London, United Kingdom
14 Day EBA Study of PA-824, Bedaquiline, Pyrazinamide and Clofazimine in Smear-Positive TB Patients
Andreas Diacon
Department of Medical Biochemistry, Stellenbosch University, Cape Town, South Africa
CTX Prophylaxis Discontinuation Among ART-Treated Adults: A Randomized Non-Inferiority Trial
Christina S. Polyak
Military HIV Research Program, Walter Reed Army Institute of Research, University of Washington, Bethesda, MD, United States
Discussion Leader
Stephen Taylor
Birmingham Heartlands Hospital, Birmingham, United Kingdom
Pharmacokinetics of Raltegravir 400 vs 800 mg BID With Intermittent Rifampicin Dosed Thrice Weekly
Saye H. Khoo
University of Liverpool, Liverpool, United Kingdom
Relationship Between Efavirenz Trough & CYP2B6 Genotypes With Rifampin-Based TB Therapy in STRIDE
Anne Luetkemeyer
HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, United States
Pharmacokinetics of Faldaprevir and Antiretrovirals in Patients With HIV/HCV Coinfection
Jürgen K. K. Rockstroh
Department of Medicine I, University of Bonn, Bonn, Germany
Relative Genetic Contribution To the Pharmacokinetics of Commonly Prescribed Antiretrovirals
Marco S. Siccardi
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
Leveraging Genomics in HIV Treatment Decisions
Paul J. McLaren
The Swiss HIV Cohort, Lausanne, Switzerland
Discussion Leader
Kevin E. Yarasheski
Washington University School of Medicine, St Louis, MO, United States
Geriatric Syndromes Are Common Among Older HIV-Infected Adults
Meredith Greene
Medicine-Geriatrics, University of California San Francisco, San Francisco, CA, United States and San Francisco VA Medical Center, San Francisco, CA, United States
Physical Function Impairment On Quality of Life Among Persons Aging With HIV Infection
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, United States
Cell-Mediated CMV Responses in HIV-Infected Persons With Impaired Physical Function
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, United States
Frailty, Inflammation and Mortality Among Aging HIV-Infected and At-Risk Injection Drug Users
Damani A. Piggott
The Johns Hopkins University, Baltimore, MD, United States
Brisk Walking Improves Inflammatory Markers in cART-Treated Patients
Valeria Longo
Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
Discussion Leader
Peter W. Hunt
University of California San Francisco, San Francisco, CA, United States
Rapid Gut-Homing of Plasmacytoid Dendritic Cells During Acute SIV Infection
R. Keith Reeves
NEPRC, Harvard Medical School, Southborough, MA, United States
CCR6+ and CD161+ CD4 T Cell Loss Contributes To the Pathogenesis of SIV Infection in Rhesus Macaques
Colleen S. McGary
Department of Microbiology and Immunology, Emory University, Atlanta, GA, United States
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
99
|
